Regentis Biomaterials Ltd. (RGNT)
NYSEAMERICAN: RGNT · Real-Time Price · USD
1.890
-0.090 (-4.55%)
At close: Sep 28, 2026, 4:00 PM EDT
1.900
+0.010 (0.53%)
Pre-market: Sep 29, 2026, 6:07 AM EDT
Company Description
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States.
It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
The company was incorporated in 2004 and is based in Herzliya, Israel.
Regentis Biomaterials Ltd.
| Country | Israel |
| Founded | 2004 |
| IPO Date | Dec 4, 2025 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| CEO | Ehud Geller |
Contact Details
Address: 60, Medinat Hayehudim, Entrance C Herzliya, 4676652 Israel | |
| Phone | 972 9 960 1917 |
| Website | regentis.co.il |
Stock Details
| Ticker Symbol | RGNT |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 1912966 |
| CUSIP Number | 001219096 |
| ISIN Number | IL0012190968 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ehud Geller Ph.D. | Chief Executive Officer and Executive Chairman |
| Arie Gordashnikov CPA | Chief Accounting Officer |
| Dr. Dror Seliktar Ph.D. | Co-Founder and Chief Scientific Officer |
| Ori Gon | Chief Financial Officer and Chief Business Officer |
| Dr. Galit Reske Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 22, 2026 | EFFECT | Notice of Effectiveness |
| Sep 17, 2026 | POS AM | Post-Effective amendments for registration statement |
| Sep 11, 2026 | 6-K | Report of foreign issuer |
| Aug 13, 2026 | SCHEDULE 13G | Filing |
| Aug 11, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 20, 2026 | 6-K | Report of foreign issuer |
| Jul 15, 2026 | 6-K | Report of foreign issuer |
| Jul 13, 2026 | EFFECT | Notice of Effectiveness |
| Jul 13, 2026 | 424B3 | Prospectus |
| Jul 9, 2026 | 6-K | Report of foreign issuer |